Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2 048
3 557.25
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Torrent Pharmaceuticals Ltd
Cost of Revenue
Torrent Pharmaceuticals Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Cost of Revenue
-₹27.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-8%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Cost of Revenue
-₹84.5B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Cost of Revenue
-₹87.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-8%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Cost of Revenue
-₹104.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-8%
|
|
|
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
|
Cost of Revenue
-₹61.4B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-7%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Cost of Revenue
-₹34B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Torrent Pharmaceuticals Ltd
Glance View
Torrent Pharmaceuticals Ltd. has steadily carved a niche for itself as a formidable player in the global pharmaceutical landscape. Founded in 1959 in India, the company specializes in developing, manufacturing, and marketing a diverse portfolio of generic and branded formulations across therapeutic areas such as cardiovascular, central nervous system, and diabetology, among others. With a robust presence in over 40 countries and a strong focus on research and development, Torrent has established partnerships and collaborations that bolster its ability to innovate and expand its product offerings. The company’s commitment to quality and regulatory compliance is evident as it operates multiple state-of-the-art manufacturing facilities certified by global regulatory bodies, ensuring that their products meet the highest international standards. For investors, Torrent Pharmaceuticals presents a compelling opportunity characterized by steady growth and a focus on long-term value creation. In recent years, the company has demonstrated resilience despite market challenges, driven by a growing demand for affordable medicines and its strategic focus on expanding its international footprint, particularly in regulated markets. The firm’s robust pipeline of products, coupled with its strengths in key therapeutic segments, positions it well for future growth. Furthermore, Torrent’s consistent financial performance and prudent management practices reflect the core principles of value investing, making it an attractive consideration for those looking to invest in a company that not only prioritizes profitability but also contributes positively to global healthcare outcomes. As the pharmaceutical industry continues to evolve, Torrent Pharmaceuticals Ltd. stands ready to navigate the complexities ahead while delivering sustained shareholder value.
See Also
What is Torrent Pharmaceuticals Ltd's Cost of Revenue?
Cost of Revenue
-27.5B
INR
Based on the financial report for Sep 30, 2024, Torrent Pharmaceuticals Ltd's Cost of Revenue amounts to -27.5B INR.
What is Torrent Pharmaceuticals Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-8%
Over the last year, the Cost of Revenue growth was 0%. The average annual Cost of Revenue growth rates for Torrent Pharmaceuticals Ltd have been -7% over the past three years , -4% over the past five years , and -8% over the past ten years .
You don't have any saved screeners yet
